HuMax IL8

Drug Profile

HuMax IL8

Alternative Names: HuMax-IL8; HuMax-Inflam; MDX 018

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab; Medarex
  • Developer Bristol-Myers Squibb; Genmab; Medarex
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Discontinued Autoimmune disorders; Glioblastoma; Palmoplantar pustulosis

Most Recent Events

  • 01 Nov 2016 Bristol-Myers Squibb completes a phase-I clinical trial in Solid tumours in USA (IV) (NCT02536469)
  • 05 Jul 2016 Cormorant Pharmaceuticals has been acquired and merged into Bristol-Myers Squibb
  • 01 Aug 2015 Phase-I clinical trials in Solid tumours in USA (IV) (NCT02536469)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top